Bluejay Diagnostics Inc. (BJDX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Bluejay Diagnostics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $5.52 | $14.67 | $9.15 | 165.76% |
Bluejay Diagnostics Inc. (BJDX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bluejay Diagnostics Inc. ever had a stock split?
Bluejay Diagnostics Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Indranil Dey CEO | NASDAQ (CM) Exchange | 095633608 CUSIP |
| US Country | 7 Employees | 24 Jul 2023 Last Dividend | 29 Jan 2026 Last Split | - IPO Date |
Overview
Bluejay Diagnostics, Inc. is a medical diagnostics company established in 2015, with its headquarters located in Acton, Massachusetts. The company focuses on the development and commercialization of innovative diagnostic solutions for healthcare professionals. Bluejay Diagnostics leverages advanced technology through its Symphony platform to offer efficient, accurate, and accessible diagnostic tests for a range of medical conditions. This platform facilitates whole blood processing, biomarker isolation, and immunoassay preparation, aiming to revolutionize point-of-care diagnostics and monitoring in various medical settings.
Products and Services
Symphony Platform: The cornerstone of Bluejay Diagnostics' offerings, the Symphony platform integrates two essential components - the Symphony analyzer and the Symphony Cartridge. The Symphony analyzer utilizes non-contact centrifugal force to process whole blood samples, isolating biomarkers and preparing immunoassays. The Symphony Cartridge houses the necessary reagents and components, making the platform versatile and suitable for various diagnostic tests.
ALLEREYE Diagnostic Test: Specifically designed for the point-of-care diagnosis of allergic conjunctivitis, the ALLEREYE test represents Bluejay Diagnostics' dedication to improving patient outcomes. This test offers a convenient and rapid solution for identifying allergic conjunctivitis, enabling healthcare professionals to make informed decisions faster.
Symphony IL-6 Test: Currently under development, this test is aimed at monitoring disease progression in critical care settings. By measuring interleukin 6 (IL-6) levels, the Symphony IL-6 test will provide valuable information about the inflammatory response in patients, aiding in the timely and effective management of critical conditions.
Development of Cardiac Biomarkers: Bluejay Diagnostics is expanding its applications of the Symphony platform by developing tests for cardiac biomarkers such as hsTNT (high-sensitivity troponin T) and NT pro-BNP (N-terminal pro b-type natriuretic peptide). These tests are crucial for diagnosing and monitoring heart conditions, demonstrating the company's commitment to broadening the scope of its diagnostic capabilities.
